Asset Details
Do you wish to reserve the book?
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
Do you wish to request the book?
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
2018
Overview
Background
Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA during the period from diagnosis to adulthood.
Methods
All patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed. Proportions, means, and SDs were used to describe the population. Incidence rates and 95% CIs were calculated to assess adverse events. Kaplan-Meier analysis was used to compare the drug survival rates.
Results
A total of 469 patients (46.1% women) were included. Their mean age at diagnosis was 9.4 ± 5.3 years. Their mean age at biologic treatment initiation was 23.9 ± 13.9 years. The pattern of use of biologics during their pediatric years showed a linear increase from 24% in 2000 to 65% in 2014. Biologic withdrawal for disease remission was higher in patients who initiated use biologics prior to 16 years of age than in those who were older (25.7% vs 7.9%,
p
< 0.0001). Serious adverse events had a total incidence rate of 41.4 (35.2–48.7) of 1000 patient-years. Patients younger than 16 years old showed significantly increased infections (
p
< 0.001).
Conclusions
Survival and suspension by remission of biologics were higher when these compounds were initiated in patients with JIA who had not yet reached 16 years of age. The incidence rate of serious adverse events in pediatric vs adult patients with JIA treated with biologics was similar; however, a significant increase of infection was observed in patients under 16 years old.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Adult
/ Adults
/ Age
/ Antirheumatic Agents - adverse effects
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Juvenile - diagnosis
/ Arthritis, Juvenile - drug therapy
/ Arthritis, Juvenile - epidemiology
/ Biological Therapy - adverse effects
/ Biological Therapy - methods
/ Child
/ Disease
/ Drug-Related Side Effects and Adverse Reactions - diagnosis
/ Drug-Related Side Effects and Adverse Reactions - epidemiology
/ Humans
/ Juvenile idiopathic arthritis
/ Medicine
/ Patients
